4//SEC Filing
Bumpus Namandje 4
Accession 0001601830-25-000108
CIK 0001601830other
Filed
Jun 22, 8:00 PM ET
Accepted
Jun 23, 5:23 PM ET
Size
7.3 KB
Accession
0001601830-25-000108
Insider Transaction Report
Form 4
Bumpus Namandje
Director
Transactions
- Award
Stock Option (Right to Buy)
2025-06-18+22,016→ 22,016 totalExercise: $5.11Exp: 2035-06-18→ Class A Common Stock (22,016 underlying) - Award
Class A Common Stock
2025-06-18+11,008→ 47,557 total
Footnotes (2)
- [F1]Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 18, 2026 or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.
- [F2]The shares subject to this option will vest and become exercisable on the earlier of June 18, 2026 or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.
Documents
Issuer
RECURSION PHARMACEUTICALS, INC.
CIK 0001601830
Entity typeother
Related Parties
1- filerCIK 0002060594
Filing Metadata
- Form type
- 4
- Filed
- Jun 22, 8:00 PM ET
- Accepted
- Jun 23, 5:23 PM ET
- Size
- 7.3 KB